Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
EP: 5.PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
EP: 6.PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
EP: 7.Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
EP: 8.Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
EP: 9.Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
EP: 10.Case Discussion: Integrating PSMA PET for Focal Boost Optimization
EP: 11.Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
EP: 12.Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Video content above is prompted by the following:
- Briefly outline the evolving role of PSMA PET imaging in assessing for posttreatment response and how you incorporate it in your practice.
- What is your timing protocol for postradiation PSMA PET imaging?
- Do you routinely use PSMA PET for posttreatment response assessment?
- What value may PSMA-PET posttreatment imaging offer compared with PSA monitoring alone?
- What do available data demonstrate, and how do these findings inform your decisions in this setting?
- 18F PSMA-1007 PET/CT vs PSA (Kleiburg et al. Eur J Rad. 2024)
- 68GaPSMA-11 (Esen et al. J Clin Oncol. 2023.)
- 68Ga-PSMA or 18F-DCFPyL-PSMA (Sutera et al. Adv Rad Onc. 2024)
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
